| Dr Bradley Lane Ashpole, MD | |
|
1107 N Prospect Ave, Itasca, IL 60143-1408 | |
| (847) 884-8346 | |
| (847) 739-0969 |
| Full Name | Dr Bradley Lane Ashpole |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 24 Years |
| Location | 1107 N Prospect Ave, Itasca, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457516866 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | 036113854 (Illinois) | Primary |
| Entity Name | The Chicago Center For Plastic & Reconstructive Surgery Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922334226 PECOS PAC ID: 8022151778 Enrollment ID: O20100203000922 |
News Archive
A population-based study suggests that the true incidence of traumatic brain injury is about sixfold higher than official figures state.
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial—the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares—show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.
Although extensive studies have been carried out on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and evidence exists that pregnant women are at elevated risk of severe COVID-19, the impact of maternal infection on the fetus is not clear. The majority of pregnant women infected with SARS-CoV-2 are asymptomatic or experience mild symptoms.
"Just a small percentage of low- and middle-income countries' health care budgets are allocated toward the treatment and prevention of chronic diseases even though such illnesses are expected to account for 69% of global deaths by 2030," according to a paper published Wednesday in the Lancet, as part of a series on chronic disease and development, ModernHealthcare.com reports.
› Verified 6 days ago
| Entity Name | Bradley Ashpole Md Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710487095 PECOS PAC ID: 1153683008 Enrollment ID: O20180313001563 |
News Archive
A population-based study suggests that the true incidence of traumatic brain injury is about sixfold higher than official figures state.
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial—the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares—show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.
Although extensive studies have been carried out on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and evidence exists that pregnant women are at elevated risk of severe COVID-19, the impact of maternal infection on the fetus is not clear. The majority of pregnant women infected with SARS-CoV-2 are asymptomatic or experience mild symptoms.
"Just a small percentage of low- and middle-income countries' health care budgets are allocated toward the treatment and prevention of chronic diseases even though such illnesses are expected to account for 69% of global deaths by 2030," according to a paper published Wednesday in the Lancet, as part of a series on chronic disease and development, ModernHealthcare.com reports.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bradley Lane Ashpole, MD 1333 W Estate Ln E, Lake Forest, IL 60045-3623 Ph: (847) 650-5818 | Dr Bradley Lane Ashpole, MD 1107 N Prospect Ave, Itasca, IL 60143-1408 Ph: (847) 884-8346 |
News Archive
A population-based study suggests that the true incidence of traumatic brain injury is about sixfold higher than official figures state.
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial—the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares—show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.
Although extensive studies have been carried out on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and evidence exists that pregnant women are at elevated risk of severe COVID-19, the impact of maternal infection on the fetus is not clear. The majority of pregnant women infected with SARS-CoV-2 are asymptomatic or experience mild symptoms.
"Just a small percentage of low- and middle-income countries' health care budgets are allocated toward the treatment and prevention of chronic diseases even though such illnesses are expected to account for 69% of global deaths by 2030," according to a paper published Wednesday in the Lancet, as part of a series on chronic disease and development, ModernHealthcare.com reports.
› Verified 6 days ago